ADVBNasdaqServices-Medical LaboratoriesFiscal year ends June 30

Advanced Biomed Inc.

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Oct 13, 2026

$4.16+0.18 (+4.52%)

Close on Oct 19, 2026

Market cap: $6.51M
P/E (TTM): 0.8
Dividend yield: –

Advanced Biomed Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-06-30	FY 2025 2025-06-30	FY 2024 2024-06-30
Revenue	0.13	–	–
Research & Development	–	0.91	0.88
General & Administrative	4.63	1.09	1.66
Operating Expenses	6.36	1.09	2.54
Operating Income	-6.23	-1.09	–
Interest & Investment Income	–	0.02	0.05
Other Non-Operating Income	-0.03	-0.24	-0.24
Pretax Income	-6.26	-1.09	-2.78
Income Tax Expense	0.00	–	–
Income from Continuing Operations	-6.26	-1.09	–
Income from Discontinued Operations	13	-2.17	–
Net Income	6.68	-3.26	-2.78
EPS (Basic)(per share)	5.33	-3.18	-2.80
EPS (Diluted)(per share)	5.33	-3.18	-2.80
Shares Outstanding (Basic, Weighted)(shares)	1.25	1.03	1.00
Shares Outstanding (Diluted, Weighted)(shares)	1.25	1.03	1.00
EBITDA	–	-0.74	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2026

Gross margin: –
Operating margin: -4883.8%
Net margin: 5231.3%
Return on equity, FY2026: 84.8%

Financial strength

Current ratio: 9.33
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 26.2%

Valuation

P/E ratio: 0.8
Price to sales: 51.01
Price to book: 0.53
Dividend yield: –